These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30608927)

  • 1. Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma.
    Shackleford GM; Mahdi MY; Moats RA; Hawes D; Tran HC; Finlay JL; Hoang TQ; Meng EF; Erdreich-Epstein A
    PLoS One; 2019; 14(1):e0206394. PubMed ID: 30608927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer.
    Tran HC; Gardner S; Weiner HL; Liebes LF; Finlay JL
    J Oncol Pharm Pract; 2014 Jun; 20(3):229-32. PubMed ID: 23929729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases.
    Jaeckle KA; Dixon JG; Anderson SK; Moreno-Aspitia A; Colon-Otero G; Hebenstreit K; Patel TA; Reddy SL; Perez EA
    Cancer Med; 2020 Nov; 9(21):7935-7942. PubMed ID: 32885617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
    Shu Q; Antalffy B; Su JM; Adesina A; Ou CN; Pietsch T; Blaney SM; Lau CC; Li XN
    Clin Cancer Res; 2006 Aug; 12(15):4687-94. PubMed ID: 16899619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent encephaloclastic cyst induced by intraventricular topotecan.
    Mella DB; Kamiya-Matsuoka C; Liao B; Tummala S; de Groot J
    J Neurol Sci; 2015 Feb; 349(1-2):52-3. PubMed ID: 25598491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
    Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
    J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma.
    Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF
    Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962).
    Potter SL; Berg S; Ingle AM; Krailo M; Adamson PC; Blaney SM
    Pediatr Blood Cancer; 2012 Mar; 58(3):362-5. PubMed ID: 21910214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastoma cell-substrate interaction in vitro.
    Wikstrand CJ; Friedman HS; Bigner DD
    Invasion Metastasis; 1991; 11(6):310-24. PubMed ID: 1822845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.
    Choi SA; Kwak PA; Kim SK; Park SH; Lee JY; Wang KC; Oh HJ; Kim K; Lee DS; Hwang do W; Phi JH
    BMC Cancer; 2016 Sep; 16(1):723. PubMed ID: 27609092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
    Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
    Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
    Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
    Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump.
    Sonabend AM; Stuart RM; Yun J; Yanagihara T; Mohajed H; Dashnaw S; Bruce SS; Brown T; Romanov A; Sebastian M; Arias-Mendoza F; Bagiella E; Canoll P; Bruce JN
    Neuro Oncol; 2011 Aug; 13(8):886-93. PubMed ID: 21750007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma.
    Kiratli H; Koç I; Öztürk E; Varan A; Akyüz C
    Jpn J Ophthalmol; 2020 Jul; 64(4):351-358. PubMed ID: 32447585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.
    Sirachainan N; Visudtibhan A; Tuntiyatorn L; Pakakasama S; Chuansumrit A; Hongeng S
    Pediatr Blood Cancer; 2008 Jan; 50(1):169-72. PubMed ID: 16572404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
    Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
    Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.